Connor, Clark & Lunn Investment Management (CC&L)
AGIO icon

Connor, Clark & Lunn Investment Management (CC&L)’s Agios Pharmaceuticals AGIO Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.3M Sell
359,550
-90,543
-20% -$2.75M 0.03% 460
2026
Q1 		$15.2M Sell
450,093
-112,549
-20% -$3.19M 0.04% 376
2025
Q4 		$15.3M Buy
562,642
+32,544
+6% +$1.14M 0.04% 348
2025
Q3 		$21.3M Buy
530,098
+24,873
+5% +$936K 0.07% 254
2025
Q2 		$16.8M Buy
505,225
+118,702
+31% +$3.6M 0.06% 279
2025
Q1 		$11.3M Buy
386,523
+260,845
+208% +$8.65M 0.05% 296
2024
Q4 		$4.13M Buy
125,678
+103,405
+464% +$4.86M 0.02% 531
2024
Q3 		$990K Sell
22,273
-15,008
-40% -$682K ﹤0.01% 893
2024
Q2 		$1.61M Buy
+37,281
New +$1.35M 0.01% 715
2024
Q1 		– Sell
-10,131
Closed -$226K – 1505
2023
Q4 		$226K Buy
+10,131
New +$227K ﹤0.01% 1241
2023
Q3 		– Sell
-80,083
Closed -$2.27M – 1341
2023
Q2 		$2.27M Sell
80,083
-42,451
-35% -$1.06M 0.01% 578
2023
Q1 		$2.81M Sell
122,534
-29,608
-19% -$786K 0.02% 483
2022
Q4 		$4.27M Sell
152,142
-41,333
-21% -$1.16M 0.02% 383
2022
Q3 		$5.47M Buy
193,475
+51,820
+37% +$1.39M 0.04% 310
2022
Q2 		$3.14M Buy
141,655
+32,767
+30% +$740K 0.02% 399
2022
Q1 		$3.17M Buy
108,888
+23,410
+27% +$715K 0.02% 402
2021
Q4 		$2.81M Sell
85,478
-18,645
-18% -$750K 0.01% 455
2021
Q3 		$4.8M Buy
104,123
+77,943
+298% +$3.77M 0.03% 347
2021
Q2 		$1.44M Buy
26,180
+17,616
+206% +$985K 0.01% 610
2021
Q1 		$442K Buy
+8,564
New +$424K ﹤0.01% 807

Other funds holding AGIO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Connor, Clark & Lunn Investment Management (CC&L)'s AGIO Position: Q2 2026 in Review

Connor, Clark & Lunn Investment Management (CC&L) reduced its Agios Pharmaceuticals (AGIO) stake by 20% in Q2 2026, selling an estimated $2.75M and leaving 359,550 shares worth $13.3M. The position accounts for 0.03% of the portfolio, ranked #460.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in AGIO in Q1 2021 and has held it in 20 quarters since. The position peaked at $21.3M in Q3 2025. 238 funds tracked by Wall St. Rank hold AGIO as of Q2 2026.

  • Connor, Clark & Lunn Investment Management (CC&L) held 359,550 shares of Agios Pharmaceuticals worth $13.3M as of Q2 2026.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 90,543 Agios Pharmaceuticals shares in Q2 2026, an estimated $2.75M.
  • Agios Pharmaceuticals made up 0.03% of Connor, Clark & Lunn Investment Management (CC&L)'s portfolio in Q2 2026, its #460 holding.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Agios Pharmaceuticals in Q1 2021 and has held it in 20 quarters since.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Agios Pharmaceuticals position peaked at $21.3M in Q3 2025.
  • 238 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q2 2026.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2026, filed 13 Aug 2026.